Nuclear Imaging for the Assessment of Cardiotoxicity from Chemotherapeutic Agents in Oncologic Disease
- 7 May 2021
- journal article
- review article
- Published by Springer Nature in Current Cardiology Reports
- Vol. 23 (6) , 1-9
Abstract
Purpose of Review In this review, we summarize the major known cardiac toxicities of common chemotherapeutic agents and the role of nuclear cardiac imaging for the surveillance and assessment of cancer therapeutics–related cardiac dysfunction in routine clinical practice. Recent Findings Cardiotoxicity from chemotherapy causes a significant mortality and limits potentially life-saving treatment in cancer patients. Close monitoring of cardiac function during chemotherapy is an accepted method for reducing these adverse effects especially in patients with cancer therapeutics–related cardiac dysfunction. Nuclear imaging is a sensitive, specific, and highly reproducible modality for assessment of cardiac function. Summary Nuclear imaging techniques including equilibrium radio nucleotide angiography, myocardial perfusion imaging, and novel experimental molecular imaging are the various objective tools available in addition to conventional echocardiography and cardiac magnetic resonance imaging in the surveillance, assessment, and follow-up of cancer therapeutics–related cardiac dysfunction.Keywords
This publication has 48 references indexed in Scilit:
- Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF InhibitorJournal of Clinical Oncology, 2013
- Adjuvant Trastuzumab in HER2-Positive Breast CancerNew England Journal of Medicine, 2011
- 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicityEuropean Journal of Cancer, 2007
- Congestive heart failure is a rare event in patients receiving imatinib therapyBlood, 2007
- Long-Term Cardiac Tolerability of Trastuzumab in Metastatic Breast Cancer: The M.D. Anderson Cancer Center ExperienceJournal of Clinical Oncology, 2006
- Angiogenesis Inhibitors and Hypertension: An Emerging IssueJournal of Clinical Oncology, 2006
- Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapyLeukemia & Lymphoma, 2005
- Comparison and reproducibility of visual echocardiographic and quantitative radionyclide left ventricular ejection fractionsThe American Journal of Cardiology, 1996
- Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapyThe American Journal of Medicine, 1987
- Adriamycin-Induced DNA Damage Mediated by Mammalian DNA Topoisomerase IIScience, 1984